Protein kinases as therapeutic targets

Pharmaceutical Research

Volumn 17, Issue 11, 2000, Pages 1345-1353

  Shears, Stephen B ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Chemotherapeutic agents; Drug design; Protein kinase; Signal transduction

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; MESSENGER RNA; MONOCLONAL ANTIBODY; NATURAL PRODUCT; PHOSPHATASE; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE;

CANCER; CANCER CHEMOTHERAPY; DIABETES MELLITUS; DRUG TARGETING; DRUG UPTAKE; GENE EXPRESSION; HUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; RNA TRANSCRIPTION; TISSUE SPECIFICITY;

ANIMALS; ANTINEOPLASTIC AGENTS; DIABETIC ANGIOPATHIES; ENZYME INHIBITORS; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 0034491146     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(04)03324-0     Document Type: Letter

References (84)

1. The protein kinases of budding yeast: Six score and more
2. 1001 protein kinases redux: Towards 2000
3. The eukaryotic protein kinase superfamily
4. Protein molecules and signaling networks
5. Diabetic vascular dysfunctions: A model of excessive activation of protein kinase C
6. MIN mice
7. Non-invasive detection of fecal protein kinase C βII and ζ messenger RNA: Putative biomarkers for colon cancer
8. Protein kinase C in disease
9. Tyrosine kinase inhibition: An approach to drug development
10. Tyrosine kinase inhibitors: From the emergence of targets to their clinical development
11. Cyclin-dependent kinases: Novel targets for cancer treatment
12. Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: Possible sites for intervention with anti-neoplastic drugs
13. STAT proteins as novel targets for cancer therapy
14. Protein kinases: The eukaryotic protein kinase superfamily: Kinase (catalytic) domain structure and classification
15. Form, function, and regulation of protein tyrosine phosphatases and their involvement in human diseases
16. Protein serine/threonine phosphatases: Structure, regulation, and functions in cell growth
17. On target with a new mechanism for the regulation of protein phosphorylation
18. Tyrosine phosphorylation of protein phosphatase 2A in response to growth stimulation and v-src transformation of fibroblasts
19. Protein kinases and phosphatases: The yin and yang of protein phosphorylation and signaling
20. Zip codes direct intracellular protein tyrosine phosphatases to the correct cellular 'address
21. Ceramide activates the stress-activated protein kinases
22. Role for ceramide in cell cycle arrest
23. Characterization of a ceramide-activated protein kinase: Stimulation by tumor necrosis factor alpha
24. H-Ras and Raf-1 cooperate in the transformation of NIH3T3 fibroblasts
25. Oncogenic activation of human R-Ras by point mutations analogous to those of prototype H-Ras oncogenes
26. Oncoprotein networks
27. Signal transduction by receptors with tyrosine kinase activity
28. Phosphoinositide kinases
29. Signal perception and transduction: The role of protein kinases
30. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, a target for therapy
31. HER2/neu signal transduction in human breast and ovarian cancer
32. Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene
33. ZD4190: An orally active inhibitor of vascular endothelial growth factor signaling with broad spectrum antitumor efficacy
34. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies
35. Amphiregulin antisense oligonucleotide inhibits the growth of T3M4 human pancreatic cancer cells and sensitizes the cells to EGF receptor targeted therapy
36. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors
37. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket
38. Flk-1 as a target for tumor growth inhibition
39. Mutationally activated Met receptor mediates motility and metastasis
40. ALK expression defines a distinct group of T/null cell lymphomas ("ALK lymphomas") with a wide morphological spectrum
41. Epidermal growth factor-related peptides and their receptors in human malignancies
42. The epidermal growth factor receptor and its inhibition in cancer therapy
43. A pharmacokinetic/pharmacodynamic trial of ZD1839 (IRESSA™), a novel oral epidermal growth factor receptor tyrosine kinase (EGFR-TK0 inhibitor, in patients with 5 selected tumor types (a phase I/II trial of continuous once-daily treatment)
44. Phase I study of oral ZD1839 (Iressa™), a novel inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK): Evidence of good tolerability and activity
45. STATS and gene regulation
46. Transcriptional responses to polypeptide ligands: The JAK-STAT pathway
47. Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate Cancer cells
48. Interleukin-6 induces prostate cancer cell growth accompanied by activation of Stat 3 signaling pathway
49. DNA damage and the DNA-activated protein kinase-DNA-PK
50. The DNA-dependent protein kinase
51. Structure of DNA-dependent protein kinase: Implications for the regulation by DNA
52. DNA-dependent protein kinase stimulates an independently active, nonhomologous, end-joining apparatus
53. DNA breakage and repair
54. Requirement for an interaction of XRCC4 with DNA ligase IV for wild type V(D)J recombination and DNA double-strand break repair in vivo
55. DNA end-joining catalyzed by human cell-free extracts
56. P53-dependent cell cycle control: Response to genotoxic stress
57. Flavopiridol: The first cyclin-dependent kinase inhibitor in human clinical trials
58. UCN-01 abrogates G2 arrest through a Cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the Cdc25C phosphatase
59. Antiestrogens: Clinical applications of pharmacology
60. MAPKs: New JNK expands the group
61. Protein phosphorylation and signal transduction
62. Prolonged activation of the mitogen-activated protein kinase pathway is required for macrophage-like differentiation of a human myeloid leukemic cell line
63. Activation of raf-1, MEK, and MAP kinase in prolactin responsive mammary cells
64. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance
65. Antiapoptotic signaling in LNCaP prostate cancer cells: A survival signaling pathway independent of phosphatidylinositol3-kinase and Akt/protein kinase B
66. Phosphoinositide 3-OH kinase (PI3k) and PKB/Akt delay the onet of the p53-mediated, transcriptionally dependent apoptosis
67. Inhibition of apoptotic signaling pathways in cancer cells as a mechanism of chemotherapy resistance
68. Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway
69. Antiapoptotic signaling by the insulin-like growth factor I receptor, phosphatidylinsoitol 3-kinase, and Akt
70. The roles of 14-3-3 proteins in signal transduction
71. Protein kinase C: Structure, function, and regulation
72. Protein kinase C activation and the development of diabetic complications
73. A carboxy-terminal deletion mutant of protein kinase CβII inhibits insulin-stimulated 2-deoxyglucose uptake in L6 rat skeletal muscle cells
74. In vitro activation and nuclear translocation of NF-kappa B catalyzed by cyclic AMP-dependent protein kinase and protein kinase C
75. Regulation of alternative splicing of protein kinase C beta by insulin
76. Identification of two essential phosphorylated threonine residues in the catalytic domain of Mekk1. Indirect activation by Pak3 and protein kinase C
77. TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis
78. Ectopic expression of protein kinase CβII, δ, and ε but not βI or ζ, provide for insulin stimulation of glucose uptake in NIH-3T3 cells
79. Protein kinase C isoforms alpha, delta and theta require insulin receptor substrate-1 to inhibit the tyrosine kinase activity of the insulin receptor in human kidney embryonic cells (HEK 293 cells)
80. Protein kinase C-delta mRNA is down-regulated transcriptionally and post-transcriptionally by 12-O-tetradecanoylphorbol-13-acetate
81. Acute hyperglycemia regulates transcription and post-transcriptional stability of PKCbetaII mRNA in vascular smooth muscle cells
82. Preclinical and clinical pharmacology of antisense oligonucleotides
83. Protein kinase C-β inhibitor LY333531 ameliorates abnormal retinal hemodynamics in patients with diabetes
84. Factors affecting the activity of muscle phosphorylase b kinase